PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “DRUG THERAPY”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources

Drug therapy management: an empirical report of drug therapy problems, pharmacists' interventions, and results of pharmacists' actions.

OBJECTIVES: To determine the number and types of drug therapy problems identified by pharmacists at six community pharmacies, identify the interventions made by these pharmacists in their attempts to resolve drug therapy problems, and determine the results of the pharmacists' actions taken to resolve drug therapy problems. DESIGN: Retrospective review of patient records from pharmacies. SETTING: Six community pharmacies that had participated in Project ImPACT: Hyperlipidemia. PATIENTS: One hundred sixteen patients from Project ImPACT: Hyperlipidemia. INTERVENTION: Drug therapy problems, pharmacists' interventions, and results of pharmacists' actions were identified and categorized. Drug therapy problems were classified into seven categories, pharmacists' interventions into six categories, and results were categorized into eight types. Frequencies and descriptive statistics were calculated for the measures. RESULTS: A total of 512 initial drug therapy problems were reported for 116 patients in the 6 pharmacies. In addition to the initial interventions, pharmacists documented another 545 times in which they intervened on the original problems. There were 354 (69.1%) drug therapy problems associated with hyperlipidemia and 158 (30.9%) with other conditions. Overall, most common types of drug therapy problems were needs additional therapy (39.8%) and nonadherence to therapy (31.1%). The most common discretionary pharmacist interventions were patient education and physician communication, which occurred on average 4.63 and 3.30 times during the project period. The most common consequence of a pharmacist intervention was an increase in patient adherence, which was reported for almost half of the patients. CONCLUSION: Drug therapy management (DTM) for patients with dyslipidemias identified frequent drug therapy problems associated with both hyperlipidemia and other conditions. Pharmacists used interventions that included laboratory testing, patient monitoring, patient education, and physician communication to influence patient adherence and optimize drug therapy. Although further research is needed, the findings of this analysis are promising for the more widespread adoption of a DTM role by community pharmacists.

Adult↗

Using pharmacokinetics in drug therapy. VII: Pharmacokinetic factors influencing drug therapy in the aged.

The pharmacokinetic factors influencing drug therapy in the elderly are reviewed with special attention on dosage regimens. Deterioration in the effectiveness of drug clearance appears to be the principal pharmacokinetic factor that is altered with age. Prolonged half-life and reduced volume of distribution are the primary and secondary causes, respectively, of the altered clearance. Studies relating age to changes in the pharmacokinetics of propranolol, digoxin, quinidine, warfarin, lithium, benzodiazepines, theophylline, cimetidine, phenytoin, and kanamycin are reviewed. Decreased drug clearance in the elderly may merit a compensatory reduction in dosage, especially for drugs with a narrow therapeutic index.

Absorption↗

Developing a computer database for registering and monitoring patients on chronic drug therapy to determine drug consumption: a pilot study.

OBJECTIVES: To develop a computerised database for monitoring actual drug consumption by a group of patients on chronic drug therapy and pilot the database to assess its effectiveness. SETTING: Community based in Chitungwiza, Zimbabwe. SUBJECTS: 434 patients with asthma, hypertension, epilepsy, Diabetes mellitus or multiple conditions whose medical information was entered into the database. MAIN OUTCOME MEASURE: Accessibility of information on the exact amount of drugs being utilised by patients. RESULTS: It was possible to determine the amount of drugs being consumed by the patients on chronic drug therapy from the database. Additional information on patient demographic data as well as adverse drug reactions could be compiled from that basic data. The database could also be used to follow up patients and record any changes in their treatment regimens and other relevant clinical information. CONCLUSION: It is feasible to create a database for monitoring actual drug consumption by patients on chronic drug therapy as a way of forecasting drug requirements accurately. Such a database has more advantages over the current methods used to estimate drug requirements. It could also be very useful as an information resource centre for nation-wide use.

Chronic Disease↗

[Ambulatory treatment of anxiety disorder. Behavior therapy and drug therapy approaches].

Phobic disorders and other anxiety disorders belong to the most frequent psychiatric illnesses. Since they can be overlapped by other mental illnesses, they are often overlooked in practice. For example, comorbidity between anxiety and depression is very high. Also, personality disorders and a person's biography can lay the ground to anxiety. A typical complication of anxiety disorders is dependence of substances, predominantly of tranquilizers and alcohol. By means of a clinical case example, the topic of anxiety disorders is discussed practically and the treatment concept is detailed. Already during ambulatory care in a general practitioner's office behavioral therapeutic strategies can be implemented besides drug treatment with relatively moderate effort.

Agoraphobia↗

Antiarrhythmic drug therapy: new drugs and changing concepts.

The effective treatment of life-threatening ventricular arrhythmias (VA) leading to sudden cardiac death remains a major health problem. Cellular electrophysiological techniques that have provided insight into the underlying mechanisms of these arrhythmias have also provided a convenient classification of antiarrhythmic drugs based on their dominant electrophysiological action. Traditional pharmacological approaches to the management of VA have involved primarily class I agents. Newer drugs in this class are potent conduction depressants (class IC agents), which, however, have been limited in their clinical impact on VA because of unwanted cardiac and extracardiac side effects. Other recent approaches include the introduction of class III agents, which are thought to interrupt primarily reentrant impulses by specific prolongation of action potential duration and refractoriness without compromising normal cardiac conduction. Newer approaches may also include drugs with greater specificity of action, agents with combinations of electrophysiological effects (class I/III, I/II), drugs exemplifying novel mechanisms of action such as anion antagonism (class V), and agents controlling sympathetic neural outflow. The growing awareness of the potential proarrhythmic effects of antiarrhythmic drugs has also become important in drug development and assessment, as emphasized by the search for improved methods of drug selection (e.g., programmed electrical stimulation). Finally, the desired characteristics of a new antiarrhythmic agent are presented as a goal for future drug development.

Action Potentials↗